Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
JAMA Dermatol ; 160(3): 363-366, 2024 Mar 01.
Article in English | MEDLINE | ID: mdl-38117485

ABSTRACT

This case report describes a woman in her 30s who presented with a 3-year history of anti­PL-12 antisynthetase syndrome characterized by interstitial lung disease, arthritis, and myositis and was diagnosed with antisynthetase syndrome­associated panniculitis.


Subject(s)
Myositis , Nitriles , Panniculitis , Pyrazoles , Pyrimidines , Humans , Myositis/diagnosis , Myositis/drug therapy , Antibodies, Antinuclear , Panniculitis/diagnosis , Panniculitis/drug therapy , Genes, T-Cell Receptor , Autoantibodies
4.
Am J Dermatopathol ; 42(11): 854-857, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32310862

ABSTRACT

Cutaneous melanomas may demonstrate a variety of histopathological features and genetic abnormalities. Melanomas that arise in the setting of blue nevi, also known as "malignant blue nevus" or melanoma ex blue nevus (MBN), share a similar histopathological and mutational profile with uveal melanoma. Most uveal melanomas show characteristic GNA11 or GNAQ mutations; additional BAP1 mutation or loss is associated with the highest risk of metastasis and worst prognosis. However, the significance of BAP1 loss in melanomas ex blue nevus remains unclear. We present a case of MBN arising from the scalp of a 21-year-old woman. The diagnosis was established on histopathological findings demonstrating a markedly atypical melanocytic proliferation with increased mitotic activity, necrosis, and a focus of angiolymphatic invasion. Immunohistochemical analysis demonstrated the absence of BAP1 nuclear expression within tumor cells. Next generation sequencing detected GNA11 Q209L mutation and BAP1 loss (chromosome 3p region loss), supporting the diagnosis. We reviewed another 21 MBN cases with reported BAP1 status from the literature. MBN with BAP1 loss presented at a younger average age (41 vs. 61 years), demonstrated larger average lesion thickness (9.0 vs. 7.3 mm), and had a higher rate of metastasis (50% vs. 33%) compared with BAP1-retained MBN. BAP1 expression studies may assist in the diagnosis and management of MBN, but further research is needed.


Subject(s)
GTP-Binding Protein alpha Subunits/genetics , Melanoma/genetics , Nevus, Blue/pathology , Skin Neoplasms/genetics , Tumor Suppressor Proteins/genetics , Ubiquitin Thiolesterase/genetics , Female , Humans , Melanoma/pathology , Nevus, Blue/genetics , Scalp/pathology , Skin Neoplasms/pathology , Young Adult
6.
Pediatr Dermatol ; 34(5): e260-e264, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28804923

ABSTRACT

Hypopigmented mycosis fungoides (HMF) is the most common variant of mycosis fungoides (MF) in children. Large-cell transformation in HMF has never been reported. Herein we report a case of HMF in an 8-year-old boy who presented with a 6-year history of hypopigmented patches on the bilateral arms, lower back, buttocks, posterior thighs, and lower legs. Biopsy revealed an abnormal CD8+ epidermotropic T-cell infiltrate consistent with the diagnosis of MF. The T-cell clonality study was positive. The patient was started on narrowband ultraviolet B (NBUVB) phototherapy and topical steroids. He had a 50% reduction in his patches after 10 months of treatment, after which he developed a single annular plaque on his left thigh. The biopsy specimen demonstrated large cells that were diffusely CD8+ and CD30- . Clobetasol propionate ointment was prescribed, which led to complete resolution of the plaque within 2 weeks. NBUVB phototherapy was continued and the patient had a complete response within the following 5 months. The case is an example of exceptionally rare large-cell transformation in pediatric MF and stresses the importance of regular follow-up of these patients.


Subject(s)
Hypopigmentation/pathology , Mycosis Fungoides/pathology , Skin Neoplasms/pathology , T-Lymphocytes/pathology , Biopsy , Cell Transformation, Neoplastic , Child , Clobetasol/therapeutic use , Glucocorticoids/therapeutic use , Humans , Male , Mycosis Fungoides/therapy , Skin/pathology , Skin Neoplasms/therapy , Ultraviolet Therapy/methods
7.
J Drugs Dermatol ; 14(10): 1161-2, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26461830

ABSTRACT

Until 2011, the standard-of-care therapy for patients with hepatitis C consisted of interferon and ribavirin. The recent advent of new targeted therapies against this virus has provided more options of treatment for infected patients. Sofosbuvir, a nucleotide inhibitor of hepatitis C virus (HCV) RNA polymerase, was recently approved by the US Food and Drug Administration in 2013. Various Phase 3 trials with sofosbuvir combination therapy have reported an incidence of rash between 7% and 18%. We here describe a case of sofosbuvir-induced erythrodermic pityriasis rubra pilaris-like drug eruption.


Subject(s)
Antiviral Agents/adverse effects , Pityriasis Rubra Pilaris/chemically induced , Sofosbuvir/adverse effects , Antiviral Agents/therapeutic use , Drug Eruptions/etiology , Drug Eruptions/pathology , Hepatitis C/drug therapy , Humans , Male , Middle Aged , Pityriasis Rubra Pilaris/pathology , Sofosbuvir/therapeutic use
8.
J Infect Dis ; 211(10): 1560-5, 2015 May 15.
Article in English | MEDLINE | ID: mdl-25231015

ABSTRACT

Human polyomavirus 7 (HPyV7) is one of 11 HPyVs recently discovered through genomic sequencing technologies. Two lung transplant recipients receiving immunosuppressive therapy developed pruritic, brown plaques on the trunk and extremities showing a distinctive epidermal hyperplasia with virus-laden keratinocytes containing densely packed 36-45-nm icosahedral capsids. Rolling circle amplification and gradient centrifugation testing were positive for encapsidated HPyV7 DNA in skin and peripheral blood specimens from both patients, and HPyV7 early and capsid proteins were abundantly expressed in affected tissues. We describe for the first time that HPyV7 is associated with novel pathogenicity in some immunosuppressed individuals.


Subject(s)
Polyomavirus Infections/pathology , Polyomavirus Infections/virology , Polyomavirus/isolation & purification , Transplant Recipients , Tumor Virus Infections/pathology , Tumor Virus Infections/virology , Aged , Blood/virology , Exanthema/pathology , Exanthema/virology , Histocytochemistry , Humans , Immunocompromised Host , Immunohistochemistry , Male , Microscopy, Electron, Transmission , Skin/pathology , Skin/virology , Viremia
SELECTION OF CITATIONS
SEARCH DETAIL
...